PRECIDIAG, INC

Precidiag, Inc. employs a proprietary discovery platform to develop targeted therapeutics and companion diagnostics for a variety of diseases and disorders. Precidiag’s novel approach utilizes genomic and functional analyses of human gut microbiota, machine learning, and artificial intelligence technologies to determine and exploit the gut microbiome’s role in the cause and/or progression of certain diseases. The company currently has two areas of therapeutic focus: 1. Ulcerative Colitis ... (UC) A first-in-class oral therapeutic targeting a cause of this disease. A companion diagnostic profiles patients for prospective treatment, ensuring increased responsiveness and better outcomes. There is no cure for UC and significant unmet needs in the treatment of UC. a substantial percentage of patients who respond to a therapy will lose this response over time. More than 40% of patients with moderate to severe ulcerative colitis do not reach remission with current available therapies. The current standard of care is to treat the symptoms. Precidiag's approach offers to change the paradigm in the treatment of UC - addressing a cause of the disease. 2. Autism Spectrum Disorder (ASD) The World health organization estimates that there are 70 million people with a diagnosis of ASD. Growing insidence rates have been observed around the world. In the US 1 in 54 children will be diagnosed with ASD. In South Korea the rate is 1 in 38 children. There are acute unmet needs in this area. ASD is a behavioral diagnosis and therefore cannot be diagnosed utilizing a medical test. There are no approved therapeutics to address the core symptoms of ASD. Precidiag has, in concert with Massachusetts General Hospital, launched the largest study in the world to study the associations of gut microbiota to the symptoms experienced by individuals with ASD. The company has established associations between gut microbiota and ASD. Our objectives are the development of targeted therapeutics for ASD's core symptoms and common comorbidities experienced by individuals with ASD.More